Genomind To Exhibit At The APA Annual Meeting And The Clinical TMS Society Meeting

Genomind To Exhibit At The APA Annual Meeting And The Clinical TMS Society Meeting

Genomind Continues to Support Annual Professional Meetings

CHALFONT, PA – May 2, 2014 – Genomind, a personalized medicine company, is pleased to announce that they will attend and exhibit at the Clinical Transcranial Magnetic Stimulation (TMS) Society Meeting, held May 2-4, 2014 and the American Psychiatric Association (APA) Annual Meeting, held May 3-7, 2014, in New York City.

Genomind will have a booth and present a poster at the Clinical TMS Society Meeting on the “Prospective Naturalistic Open Label Study of Pharmacogenetic Testing in Psychiatry Patients.” The results of this study show that:

    • 89% of patients showed clinically measurable improvement after assay-guided treatment.
    • 90% of treatment resistant patients, defined as having two or more failed treatment trials, showed clinically measurable improvement after assay-guided treatment.
    • There were significant decreases in patient-reported depression, anxiety, and side effects.
    • There were significant increases in patient-reported quality of life; and
    • Both clinician-reported response rates (assessed by the CGI-I), and patient-reported response rates (assessed by the depression inventory) exceeded the seminal STAR*D depression trial for all patients, regardless of number of previous failed treatment trials.

This year’s theme of the APA Conference, “Changing the Practice and Perception of Psychiatry,” is directly related to how Genomind is disrupting the current trial-and-error model in psychiatry by providing actionable information to more effectively prescribe psychiatric medication. The Genecept™ Assay, Genomind’s core product, is a comprehensive saliva-based genetic test that helps inform clinician treatment decisions. By understanding a patient’s physiological and biological profile, clinicians can more accurately choose classes and doses of medication that will lead to increased efficacy and reduced side effects, drug-drug interactions and adverse events.

Genomind will be exhibiting at Booth #1511 at the APA conference.

About the Genecept Assay

The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit

About Genomind

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at

For more information, contact:

Adam Shapiro

Amy Pressman
Marketing Manager, Genomind


} ); } ( jQuery ) );